Global Phase 3 Trial Investigates mRNA Vaccine for Melanoma Treatment
Source: Targeted Oncology, April 2024
Jeff Yorio, MD, discussed the unmet needs among patients with melanoma and plans for a phase 3 study assessing an mRNA vaccine.
A global phase 3 clinical trial is planning to evaluate an mRNA vaccine for the treatment of patients with high-risk melanoma that have already undergone surgery. The treatment combines an individualized neoantigen therapy (V940) and pembrolizumab (Keytruda).
V940 is designed to target a patient’s specific tumor mutations and boost the immune system’s ability to fight cancer cells.Early trials suggested that V940 plus pembrolizumab may be more effective than pembrolizumab alone in reducing the risk of melanoma recurrence or death. This phase 3 trial aims to confirm these findings in a larger cohort of approximately 1089 patients.